Diabetes Treatment News, Boehringer Ingelheim

31.01.2012	FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adults with Type 2 Diabetes - For Non-U.S. and Non-UK Media
08.12.2011	Linagliptin demonstrates meaningful improvement in glycaemic control in initial combination therapy with metformin - EX US, UK and UAE Medical Media Only. Under embargo until 08 Dec, 10 am CET
17.11.2011	Boehringer Ingelheim race to the finish line in support of World Diabetes Day - EX US and UK.
16.09.2011	New data for once-daily linagliptin show durable efficacy over two years - For Medical Media outside the US and UK only.
13.09.2011	Boehringer Ingelheim and EFSD collaborate to support diabetes research in Europe - For NON-UK and NON-US / Medical Media only.
25.08.2011	Trajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe - EX US and UK / Medical Media Only.
27.06.2011	New data for linagliptin* show clinically meaningful efficacy similar to glimepiride but with fewer cardiovascular events - EX US and UK. Medical Media Only.
24.06.2011	Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe - EX US and UK. Medical Media Only.
03.05.2011	FDA approves linagliptin tablets for the treatment of type 2 diabetes - EX US and UK. Medical Media Only.
11.01.2011	Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide
15.11.2010	Boehringer Ingelheim steps up to the challenge in support of World Diabetes Day
22.09.2010	New phase III data further support the safety and efficacy profile of Boehringer Ingelheim’s investigational drug linagliptin - For non-US healthcare media
26.06.2010	Boehringer Ingelheim announces results of phase III data showing that linagliptin significantly lowered blood glucose with an excellent safety and tolerability profile - For non-US healthcare media only

31.01.2012

FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adults with Type 2 Diabetes - For Non-U.S. and Non-UK Media

08.12.2011

Linagliptin demonstrates meaningful improvement in glycaemic control in initial combination therapy with metformin - EX US, UK and UAE Medical Media Only. Under embargo until 08 Dec, 10 am CET

17.11.2011

Boehringer Ingelheim race to the finish line in support of World Diabetes Day - EX US and UK.

16.09.2011

New data for once-daily linagliptin show durable efficacy over two years - For Medical Media outside the US and UK only.

13.09.2011

Boehringer Ingelheim and EFSD collaborate to support diabetes research in Europe - For NON-UK and NON-US / Medical Media only.

25.08.2011

Trajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe - EX US and UK / Medical Media Only.

27.06.2011

New data for linagliptin* show clinically meaningful efficacy similar to glimepiride but with fewer cardiovascular events - EX US and UK. Medical Media Only.

24.06.2011

Linagliptin recommended for approval in the treatment of type 2 diabetes in Europe - EX US and UK. Medical Media Only.

03.05.2011

FDA approves linagliptin tablets for the treatment of type 2 diabetes - EX US and UK. Medical Media Only.

11.01.2011

Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide

15.11.2010

Boehringer Ingelheim steps up to the challenge in support of World Diabetes Day

22.09.2010

New phase III data further support the safety and efficacy profile of Boehringer Ingelheim’s investigational drug linagliptin - For non-US healthcare media

26.06.2010

Boehringer Ingelheim announces results of phase III data showing that linagliptin significantly lowered blood glucose with an excellent safety and tolerability profile - For non-US healthcare media only

Diabetes Video Gallery

Mode of Action of DPP-4 Inhibitors
- Watch the Video
Diabetes Complications Animation
- Watch the video
Professor Anthony Barnett: Advantages of DPP-4 inhibitors in the treatment of type 2 diabetes
- Watch the Video(WMV)
Professor Anthony Barnett: Renal impairment in type 2 diabetes
- Watch the video(WMV)
Professor Anthony Barnett: The potential of linagliptin
- Watch the video(WMV)